Replies to post #462758 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Highly statistically significant / small p-values alone doesn’t tell us how large and clinically meaningful the reduction in volume loss is.

The reduction could be very small but consistently so versus placebo and achieve great p-values.

My question is why does Anavex just release a p-values range, but not absolute numbers of reduction in brain volume loss and by brain region?

Same nonsense as with the naked odds ratios. It amounts to bs and the market seems to understand that quite well!

[nidan7500]

tschuss...

This treatment will be submitted for approval and it will be approved in multiple locations in time. Ultimately, Blarcamesine will become a treatment of choice for multiple CNS issues...and Anavex will become a mega Pharma unless bought out. In the meantime still have some buy orders sitting in case the market chooses to fill them...

...I totally concur w/this thinking...thx

IMO, eventually we will see deeper work and study until CNAS diseases evolve as treatable for future populations.